Predictors of b/tsDMARDs discontinuation and treatment response in psoriatic arthritis: results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR-PsA)

Clicks: 13
ID: 337430
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #298 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Despite advances in biologic and targeted synthetic DMARDs (b/tsDMARDs), many patients with psoriatic arthritis (PsA) experience suboptimal responses and discontinue therapy. We aimed, in a real-world registry, to identify predictors of b/tsDMARD discontinuation and treatment response. METHODS: Patients commencing b/tsDMARD therapy were identified from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‑PsA). Clinical and patient‑reported measures were collected at treatment start. Cox regression identified predictors of drug discontinuation using multiple imputation with predictive mean matching to handle missing data, and logistic regression identified predictors of achieving 12-month Minimal Disease Activity (MDA), ACR50 and PsARC response. RESULTS: Eight-hundred and fifteen participants were included; 40% male, median age 51 years, with high disease activity (median DAPSA 33.5; PASDAS 5.9). At censoring (01‑Aug‑2025), 65% remained on their index therapy (median exposure 31 months) with discontinuation primarily due to inefficacy (55%) or intolerance (26%). Patients commencing PDE4 inhibition experienced more than a doubling in the risk of discontinuation, compared to those starting TNF inhibitors (Hazard Ratio: 2.25; 95%CI: 1.45-3.50), while no major differences were observed with other modes of action. At 12-months, 24% achieved MDA, 24% ACR50, and 49% PsARC. Based on imputed outcomes, men, younger individuals, and those who were employed were consistently more likely to achieve treatment response, while poorer baseline clinical or patient‑reported measures predicted non‑response. CONCLUSIONS: Treatment persistence and response in PsA remain a problem and are strongly influenced by demographic factors and baseline disease severity. A better understanding of predictors of non-response may aid future risk stratification.
Reference Key
openalex_W7224012425 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ovidiu Rotariu, Stephanie Lembke, Philip Helliwell, Stefan Siebert, Gary John Macfarlane, Gareth Tudor Jones
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag598
URL
https://doi.org/10.1093/rheumatology/keag598
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.